VIP

Mechanism

VIP is a naturally occurring 28-amino-acid peptide that your body uses to regulate blood flow, immune responses, and the function of many organs including the gut, lungs, and brain. It acts as a powerful anti-inflammatory agent and has been studied for conditions like chronic inflammatory response syndrome (CIRS), pulmonary hypertension, and autoimmune disorders. VIP also supports circadian rhythm regulation and helps maintain the protective barriers in your gut and lungs.

Effects

**Immune/Inflammatory System (Tier 1 — Extensively Studied Neuropeptide):** VIP (vasoactive intestinal peptide) is a 28-amino acid neuropeptide with broad anti-inflammatory and immunomodulatory activity. It signals through VPAC1 and VPAC2 receptors (G-protein coupled, cAMP-linked) expressed on virtually all immune cells. Effects: (1) potent suppression of pro-inflammatory cytokines (TNF-alpha, IL-6, IL-12, IL-1beta) from macrophages and dendritic cells via NF-kB inhibition; (2) induction of regulatory T cells (Tregs) and tolerogenic dendritic cells; (3) shift from Th1/Th17 → Th2/Treg immune profile; (4) inhibition of NLRP3 inflammasome activation. **Pulmonary System (Tier 1 — Critical for CIRS):** VIP is the most potent known endogenous pulmonary vasodilator. It relaxes pulmonary arterial smooth muscle, reduces pulmonary artery pressure, and increases pulmonary blood flow. In the airways: bronchodilation, inhibition of mucus hypersecretion, and suppression of airway inflammation. VIP deficiency in lung tissue is a hallmark of CIRS/mold illness (Shoemaker finding) and contributes to the exertional dyspnea, pulmonary hypertension, and reduced exercise tolerance seen in CIRS patients. **Gastrointestinal System (Tier 1):** VIP is a major regulatory neuropeptide of the enteric nervous system ("gut brain"). It relaxes GI smooth muscle (including lower esophageal sphincter, pyloric sphincter, intestinal wall), stimulates water and electrolyte secretion, inhibits gastric acid secretion, promotes pancreatic bicarbonate secretion, and maintains intestinal mucosal blood flow. Dysfunction of VIP signaling contributes to GI dysmotility, SIBO, and gut barrier dysfunction. **Cardiovascular System (Tier 1):** Systemic vasodilation (hypotension is the dose-limiting side effect), positive inotropic and chronotropic effects on the heart, coronary artery vasodilation. VIP acts as a counter-regulatory peptide to the sympathetic/catecholamine system. **Neuroendocrine/CNS (Tier 1):** VIP is a neurotransmitter/neuromodulator in the CNS. Functions in circadian rhythm regulation (VIP neurons in the SCN of hypothalamus), neuroprotection against oxidative stress and excitotoxicity, regulation of the HPA axis, and modulation of neuroinflammation. VIP deficiency may contribute to the cognitive dysfunction ("brain fog"), sleep disturbance, and mood changes seen in CIRS. **CIRS-Specific Pathophysiology (Tier 2 — Shoemaker Protocol):** In CIRS (Chronic Inflammatory Response Syndrome), biotoxin exposure (mold, Lyme, ciguatera) triggers a self-perpetuating inflammatory cascade. VIP levels are characteristically LOW in CIRS patients. VIP deficiency contributes to: elevated TGF-beta1, elevated C4a, elevated MMP-9, low MSH (alpha-melanocyte stimulating hormone), pulmonary hypertension (reduced PASP on echocardiogram), reduced VEGF, and persistent inflammatory cytokine elevation. VIP replacement is the FINAL step in the Shoemaker protocol — administered only after all upstream steps are completed.

Practitioner Guide

**Shoemaker CIRS Protocol — Nasal VIP (Step 12, Final Step):** - Prerequisites (ALL must be completed before starting VIP): 1. Remove from exposure (mold remediation or relocation) 2. Cholestyramine/Welchol binder therapy (Step 2) 3. MARCoNS eradication confirmed by negative nasal culture (Step 6) 4. Correct abnormal ADH/osmolality (DDAVP if needed) (Step 7) 5. Correct elevated MMP-9 (high-dose omega-3, no-amylose diet) (Step 8) 6. Correct VEGF abnormalities (Step 9) 7. Correct elevated C3a (statins if needed) (Step 10) 8. Correct elevated TGF-beta1 (losartan if elevated) (Step 11) - CRITICAL: Starting VIP before MARCoNS eradication may WORSEN outcomes — VIP can promote biofilm growth if active nasal staph colonization is present **Nasal VIP Protocol:** - Formulation: VIP compounded into nasal spray, typically 50mcg per spray (0.1mL of 500mcg/mL solution) - Dose: 1-4 sprays each nostril, 4 times daily (starting dose: 1 spray each nostril 4x/day = 400mcg/day) - Titrate up based on response and tolerance over 2-4 weeks - Target dose: typically 2-4 sprays per nostril QID (800-1600mcg/day total) - Duration: 1-3 months initially; some patients require ongoing maintenance **What CIRS Practitioners Observe:** - Rapid improvement in: shortness of breath / exertional dyspnea (often within days), cognitive function ("brain fog" clearing), fatigue levels, and overall quality of life - Lab improvements: TGF-beta1 normalization, C4a reduction, MMP-9 reduction, VEGF improvement, pulmonary artery systolic pressure normalization on echocardiogram - MSH (alpha-melanocyte stimulating hormone) levels often increase back toward normal — indicating restoration of neuroimmune signaling - The response to VIP is one of the most dramatic in the Shoemaker protocol — patients who have been chronically ill for years often report significant improvement within 1-2 weeks **Common Issues and Management:** - Hypotension/lightheadedness: the most common side effect (VIP is a vasodilator) — usually mild and transient; worse with first few doses; have patient sit/lie down after initial doses - Nasal congestion/rhinorrhea: common initially; usually resolves in 1-2 weeks - Diarrhea: VIP stimulates intestinal secretion — reduce dose if GI symptoms are bothersome - Headache: occasional; usually mild and self-limiting - If symptoms WORSEN on VIP: re-check MARCoNS culture (positive culture = stop VIP until eradicated), re-check exposure (ensure patient is in clean environment) **VIP Beyond CIRS:** - Pulmonary hypertension: inhaled VIP (not nasal) has been studied in WHO Group I PAH — improved hemodynamics and exercise capacity in small trials - Autoimmune conditions: VIP's immunomodulatory profile (Treg induction, Th17 suppression) has theoretical applications in RA, MS, IBD, and type 1 diabetes — mostly preclinical data - Sarcoidosis: some CIRS practitioners use nasal VIP for sarcoid-associated inflammation with reported benefit **Compounding and Storage:** - VIP must be compounded by a specialty compounding pharmacy (not commercially available as a pharmaceutical in the US) - Nasal spray: compound at 500mcg/mL in sterile nasal spray vehicle - Store refrigerated (2-8C); VIP is a fragile peptide — avoid heat, light, and contamination - Use within 30 days of compounding (some pharmacies provide 60-day dating) - Ensure pharmacy uses pharmaceutical-grade VIP with certificate of analysis

Dosing Protocols

Contraindications & Cautions

• hard stop — Pregnancy
  No adequate human safety data for therapeutic VIP during pregnancy. VIP plays complex roles in placental development and uterine blood flow; exogenous administration could disrupt these processes.
  Action: Do not use during pregnancy.
• hard stop — Breastfeeding
  No data on effects of exogenous VIP on breast milk or nursing infant. Safety not established.
  Action: Do not use while breastfeeding.
• hard stop — Under 18 years of age
  Peptide protocols are not designed for pediatric use.
  Action: Do not provide to individuals under 18.
• requires physician — Hypotension
  VIP is a potent vasodilator. Patients with baseline hypotension or orthostatic hypotension may experience dangerous further blood pressure reduction.
  Action: Requires physician evaluation. Monitor blood pressure closely during administration. Have vasopressor support available.
• caution — Chronic diarrhea or VIPoma
  VIP stimulates intestinal secretion and can cause or worsen diarrhea. In patients with VIP-secreting tumors (VIPomas), exogenous VIP would compound the secretory diarrhea.
  Action: Monitor for diarrhea. Avoid in patients with known VIPoma. Adjust dose if GI symptoms are significant.
• caution — Active cancer
  VIP has immunomodulatory properties that shift toward anti-inflammatory/tolerogenic immunity. Theoretical concern that immune suppression could reduce anti-tumor surveillance.
  Action: Use with caution in patients with active cancer. Consult oncologist.

Research Summary

**Tier 1 — Extensively Studied Neuropeptide:** - VIP is one of the most-published neuropeptides in biomedical literature (>15,000 PubMed entries) - Discovery: Sami Said & Viktor Mutt, 1970 — originally identified for its vasodilatory properties - Comprehensive pharmacology: VPAC1, VPAC2 receptor signaling, cAMP-PKA pathway, NF-kB inhibition — thoroughly characterized - Anti-inflammatory effects documented in hundreds of studies: colitis, arthritis, sepsis, encephalomyelitis, airway inflammation models - Immune modulation: Treg induction by VIP-treated dendritic cells (Gonzalez-Rey, Chorny, Delgado — multiple high-impact publications) **Tier 2 — Clinical Studies:** - Inhaled VIP for pulmonary hypertension: Petkov et al. (Am J Respir Crit Care Med, 2003) — improved pulmonary hemodynamics and exercise capacity in PAH patients - Shoemaker CIRS protocol: published case series and observational data showing VIP normalization of TGF-beta1, C4a, MMP-9, and PASP in CIRS patients (Shoemaker & House, 2006-2012) - VIP deficiency in CIRS: Shoemaker documented low VIP levels in CIRS patients vs. controls, with correlation to disease severity - Erectile dysfunction: intracavernous VIP + phentolamine (Invicorp) — approved in some countries for ED treatment **Tier 3 — Emerging/Experimental:** - VIP analogs with improved stability (native VIP has <2 min plasma half-life): lipidated VIP, PEGylated VIP, and VIP receptor agonists in development - VIP in type 1 diabetes: preclinical data showing prevention/reversal of autoimmune diabetes via Treg induction - VIP in inflammatory bowel disease: strong preclinical rationale; early clinical exploration - VIP nanoparticle delivery systems for targeted anti-inflammatory therapy - VIP in neurodegenerative disease: neuroprotection data in Alzheimer's and Parkinson's models - VIP in COVID-19: FDA granted Emergency IND for inhaled VIP (Aviptadil/Zynquista) in severe COVID-19 ARDS — mixed trial results; not approved but demonstrated biological activity in ARDS/acute lung injury